Articles by Louis Garguilo

31. Biogen's Outsourcing Trifold For Joint Value Creation 3/22/2016

    Purposeful segmentation, descriptive scorecards and matrixes, and CMO governance, form a trifold of strategic relationship management for Biogen’s supply chain, says Thomas Holmes, senior director for Global External Manufacturing.  

32. In Outsourcing, Genzyme Sees An Advantage 3/16/2016

    Regarding the outsourcing of biologics manufacturing, Piet Houwen of Sanofi says, “Starting from today, where I’d say the market relationship is sixty percent driven by the sellers, I believe we’ll see a change to a move in the direction of the sponsors.”

33. Is The Virtual Biotech Model In Jeopardy? 3/10/2016

    It appeared we were coasting uninterrupted to a global outsourcing industry fully able to support a wide variety of virtual business models and strategies. But conversations with executives at established biotechs reveal an unfolding reality.

34. At Biogen, Three Keys To Outsourcing 3/2/2016

    Thomas Holmes, senior director for Global External Manufacturing, Biogen, says: (a) cost is not the strategic driver in CMO selection; (b) “dual sourcing” is revenue independent; and (c) the time from drug approval to market launch is all of 48 to 72 hours. 

35. Biopharma Climbs The Serialization Mountain 2/11/2016

    The data associated with drug-product serialization will be Everest-like; accessing it may pose every bit the security risk. The difference is millions of people may be trying to access the summit … every day. What’s clear today is that a national program for drug serialization looms large on the horizon, and rises, if you will, high into the data clouds.

36. Drug Serialization Reaching Consumers 2/8/2016

    Three years into a U.S. initiative for drug “serialization,” companies are: (a) working with the FDA; (b) taking their own steps to traceability; and/or (c) hoping the day of reckoning fades further into the future. But the future is here with serialization reaching into the consumer’s home. 

37. Is Marketing Manipulating Your CMO Selection? 2/2/2016

    A report on biologics API outsourcing provides insights on how marketing and reputation influences BioPharma's selection of CMOs. Both sides need to line up actual CMO performance and capabilities with market perceptions. But sponsors beware: Under a marketing spell, it appears the best strategy to select CMOs is to find those perceived as most expensive.

38. More Biotech Mixology For Successful Outsourcing 1/25/2016

    Last we left off, M. (Ken) Kengatharan, PhD, MBA, serial start-up entrepreneur and scientist – or biotech mixologist – was mixing examples of outsourcing that included falsely inflated balloons and Super Hero deliveries of API. Here Kengatharan draws some final lessons and insights into successful outsourcing. 

39. Outsourcing Lessons From A Biotech Mixologist 1/19/2016

    M. (Ken) Kengatharan is an accomplished mixologist. What he mixes professionally is biotech business models, drug researchers and developers, private and venture capital, entrepreneurs and investors … with a large shot of strategic outsourcing. Through his experiences at the five biotechs he’s put together, we can learn how to improve sponsor and service-provider dynamics.

40. Pharmaceutical Outsourcing: What Are You Thinking? 12/17/2015

    In this final editorial of 2015, we look into the collective mind of the outsourcing industry, and select a leader of the year. The biopharma industry is now second to none in global consciousness and importance, and the significance of outsourcing within that heightened position grows in equal measure. Prepare well for 2016.